Skip to content

Selling a Pharmacy

Pharmacy Exit Planning: A Timeline for Selling

11 November 2026 · 10 min read

Get in touch

The gap between a pharmacy sale that maximises value and one that does not is mostly determined by what happened in the two to three years before the sale, not in the weeks around it. By the time a buyer is at the table, the accounts are what they are, the BADR qualifying conditions either hold or they do not, and the NHS regulatory clock has either started or it has not.

The exit runs in phases: what to tackle early, what belongs in the middle period, what the final twelve months require, and what needs to be in place at completion. For the readiness checklist (what to fix in your accounts), see preparing a pharmacy for sale. For the deep tax mechanics, see the pharmacy sale CGT and BADR service.

When to start planning a pharmacy exit

Start two to three years before the target disposal date. The biggest levers are a clean, reconciled margin story that supports the price a buyer will pay, the deal structure, and timing the sale around the BADR rate and your CGT position. All three take time to put in place. The BADR qualifying period is at least two years of trading ownership; the NHS contract change-of-ownership process under the 2013 Regulations runs on its own long timeline; and a buyer's due diligence will want three years of clean, reconciled accounts. None of those can be compressed in the final months before exchange.

The exit timeline, phase by phase

Here are the main value actions and tax actions, phase by phase. It's a planning framework, not a legal or tax opinion; every situation has specific facts that change the calculation.

Phase Value action Tax / structure action Why it matters
Early (2-3 years out) Start producing monthly management accounts that separate NHS reimbursement, Drug Tariff margins, OTC retail and service income. Annotate Drug Tariff adjustment months. File FP34 NHSBSA payment schedules. Check BADR qualifying conditions: two-year ownership, officer/employee status, 5% shares and votes. Note prior use of the £1m lifetime limit. Flag any restructuring planned (it can reset the clock). Three years of clean accounts is the buyer's minimum. BADR conditions must be met at disposal, so the clock starts now.
Mid period (12-24 months out) Review VAT retail-scheme choice and document the basis. Separate Pharmacy First and other service income as a distinct revenue line. Confirm dispensing item volume trend is evidenced month by month. Model the expected gain and check whether it is within the BADR £1m lifetime limit (£500,000 for disposals from 6 April 2027, if the Budget change becomes law), within the basic-rate band, or above. Consider whether deal structure (share vs asset) changes the BADR eligibility or the buyer's stamp duty exposure. Assess whether earn-out or deferred consideration is likely and what that does to the timing of tax. VAT inconsistency is a due-diligence red flag that transfers on a share purchase. Structure decisions made before heads of terms are signed; reversing them later is costly.
Final 12 months Assemble the three-year margin-story document: revenue by line, Drug Tariff variance annotations, FP34 schedule, VAT-scheme disclosure. Confirm the premises entry in the GPhC register is current (it's renewed each year, Medicines Act 1968 s74A) and understand the change-of-ownership regulatory steps. Confirm BADR qualifying conditions still hold. Check remaining lifetime limit. Agree deal structure and earn-out mechanics with advisers before heads of terms. Consider the disposal-date decision in relation to the current tax year and rate. The margin story is presented to buyers early in the process. The regulatory process under the 2013 Regulations needs to start in parallel with legal, not after it.
At completion Data room is ready: three years of accounts, FP34 schedules, VAT-scheme records, GPhC and NHS contract documentation, employee records. Exchange date determines the BADR rate and the tax year. A fixed deferred amount is taxed at the disposal date; each payment under a contingent earn-out is a separate disposal of the right to it, without BADR, so track them separately. File the CGT return within 60 days of completion for residential elements; annual Self Assessment for the rest. A buyer's due-diligence team will interrogate every line. Delays from missing records push completion back and can reopen price negotiation.

The tax-timing lever: BADR, CGT bands and the disposal date

Business Asset Disposal Relief reduces the CGT rate to 18% for 2026/27 on qualifying gains up to the £1m lifetime limit per person. From 6 April 2027 the lifetime limit is due to fall from £1 million to £500,000 (announced at Budget 2026 on 28 October 2026, still to pass in the Finance Bill). The rate was 14% in 2025/26 and 10% before that. The disposal date (normally the exchange date, not completion) determines which rate applies. Special rules apply where contracts are exchanged before 6 April 2027 but complete on or after it: the £500,000 limit can still apply unless the parties to the contract can show it was not entered into to gain a tax advantage from the timing (and, where they are connected, that it was for wholly commercial reasons), so exchanging early is not a safe way to keep the £1m limit.

Gains beyond the BADR limit are taxed at 24%, because the BADR gain uses up the basic-rate band first. Where BADR does not apply, standard CGT rates are 18% within the remaining basic-rate band and 24% above it. The basic-rate band ceiling is £37,700. The annual exempt amount is frozen at £3,000.

Gain type Rate for 2026/27 Notes
BADR-qualifying (up to £1m lifetime limit) 18% Qualifying conditions must be met at exchange; lifetime limit is per person, not per company
Standard CGT within remaining basic-rate band 18% Basic-rate band ceiling £37,700; income for the year is taken into account first
Standard CGT above basic-rate band 24% Applies to the excess
Annual exempt amount £3,000 deducted from total gain Frozen at £3,000

Sources: gov.uk/business-asset-disposal-relief and gov.uk/capital-gains-tax/rates.

Deferred consideration and earn-outs are taxed in two different ways. A fixed deferred amount counts in full at the date of disposal, with no discount for waiting (HMRC manual CG14881, TCGA 1992 s48); if it's paid in instalments over more than 18 months, you can ask to pay the tax in instalments as well (CG14910). A contingent earn-out, one that turns on profits after the sale, is valued as a right at the disposal, and each payment you later receive is a disposal of that right. Those later gains don't get the relief claimed on the original sale, BADR included (CG14970), and they land in later tax years against your other income then. So how the deal documents describe the deferred money is a planning variable worth running properly, subject to your specific facts.

Timing around the BADR rate step and your CGT band can be material, subject to your facts. Do not treat disposal timing as a formality. For a modelled computation, visit the pharmacy sale CGT and BADR service page or speak to us directly.

Put in the sale price, your base cost and the completion date to see the capital gains tax under today's BADR lifetime limit and under the lower limit announced from 6 April 2027.

Calculator

Pharmacy sale tax estimator: what you pay before and after the April 2027 BADR change

Put in the price, what the pharmacy or your shares cost you, your selling costs and any BADR you've already used. We'll show the CGT with BADR's £1 million lifetime limit, the CGT with the £500,000 limit announced for disposals from 6 April 2027 (still to pass in the Finance Bill), the difference, and when the tax's due. It's for a sole trader or partner selling the business, or a shareholder selling their shares. Every figure already in the boxes is an example, so replace it with your own.

If the company sells the business, the company pays corporation tax on its gain, not CGT, and BADR doesn't apply to it. This tool doesn't cover that route.

£

What you're getting for the business or your shares, including any fixed sum paid after completion. If you own the pharmacy with someone else, enter your own share: each owner has their own BADR limit and annual exempt amount. For an earn-out that depends on future results, include only what the right to it is worth at the sale.

£

For a business you bought, what you paid for the goodwill and the other assets you're now selling, plus the costs of buying them. For shares, what you paid for them. If you opened the pharmacy yourself, there may be little or nothing here.

£

Money spent adding to the value of what you're selling (not repairs or running costs), plus the costs of the sale itself, such as broker, legal and valuation fees.

For CGT a sale happens when the contract's made, or when its last condition's met, not at completion (TCGA 1992 s28). That's why the next box matters if you complete on or after 6 April 2027.

£

The total of gains you've claimed BADR (or Entrepreneurs' Relief, its old name) on in earlier sales. They count against the £1 million now and, as announced, against the £500,000 too.

£

Salary, business profits, pension, rent, dividends and interest. We take off the standard £12,570 Personal Allowance to find how much of the £37,700 basic-rate band is left. Your BADR gain uses the band first, so it only changes the figures for gain outside BADR.

£

Gains on anything else you sell in the same tax year, less any losses. They're taxed at 18% or 24% too, and they share your annual exempt amount.

Your result

Your answer's ready. Press below to see it.

The value levers: what to fix early so the accounts tell the right story

Pharmacy valuation is anchored on the quality and defensibility of the income, not just its size. A buyer is acquiring the NHS contract and the income stream it generates; the physical premises and stock are secondary. The value levers that determine how a buyer reads that income are within an owner's control, but they take time to fix.

Category M and Drug Tariff margin story

Under the Drug Tariff and Category M mechanism, gross margin is set centrally and moves as DHSC resets Category M prices each quarter. A buyer's accountant will test whether margin swings are explained or unexplained. Unexplained variance is priced in as risk, which means a lower offer. The fix is management-account annotations that record which months were affected by Drug Tariff adjustments and why, so the variance is transparent, not suspicious.

Dispensing volume (items per month) is the proxy a buyer uses for NHS contract strength. A consistent or growing volume trend over three years is the account-level evidence that the contract income is durable. Start tracking it as a formal management metric now if it is not already.

FP34 and NHS income cleanliness

The FP34 NHSBSA payment cycle drives pharmacy cash flow: prescriptions submitted monthly, then two NHSBSA payments: an advance of the full estimate around the 10th of the next month and a reconciliation roughly two months after submission. Three years of FP34 payment schedules reconciled to bank statements is the minimum a buyer's due diligence requires. Missing months, unreconciled advances, or gaps in the payment log are due-diligence red flags that delay completion and invite price chip.

Income coding matters too. Pharmacy First and other service income should be coded as a separate line from NHS reimbursement and remuneration. A buyer paying for a growing service line cannot verify it if it is buried in a catch-all income code.

VAT mix and retail-scheme consistency

A community pharmacy is a VAT-mixed business: NHS-dispensed prescription drugs are zero-rated; over-the-counter medicines are standard-rated. The retail scheme chosen to split takings must be appropriate and consistently applied across the three years the buyer will scrutinise. On a share purchase, inconsistent VAT treatment transfers as an audit risk to the buyer; they will either price it in or require a warranty. Reviewing and documenting the scheme basis early removes this risk from the negotiation.

Goodwill and what drives it

Goodwill dominates pharmacy pricing because what a buyer is acquiring is primarily the NHS contract and the item volume it supports. For a buyer that buys the business through a company, corporation tax relief on goodwill is restricted: a fixed 6.5% a year, and none while the goodwill's held unless qualifying IP assets are bought with it. This affects the buyer's after-tax economics and can influence whether they prefer a share purchase or an asset deal. Understanding the goodwill position from the seller's side helps anticipate how a buyer will structure their offer.

For the mechanics of how pharmacy goodwill is assessed, see the pharmacy goodwill valuation post.

Want this checked against your specific situation?

Leave your details and a one-line summary. One of our specialists will come back to you, with no obligation.

We'll only use your details to respond to your enquiry. We don't pass them to any other firm. See our Privacy Policy.

Structure and the contract-transfer reality

The deal structure decision sits between two options, each with different tax and regulatory implications.

A share purchase means the buyer acquires the company and its full history: liabilities, warranties, VAT records, employment obligations and all. Stamp duty is 0.5% on the share consideration for now; the Securities Transfer Tax announced to replace it is due in late 2027, by commencement order. Source: gov.uk/tax-buy-shares. The NHS contract stays with the company, which simplifies the regulatory position but means the buyer inherits the company's past.

An asset purchase means the buyer selects which assets to acquire. If property transfers, SDLT applies at non-residential and mixed-use rates, reaching 5% on the slice above £250,000. The buyer does not inherit the company's history, but the NHS contract position is more complex because the contract is held by the entity, not the assets.

Under the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013, an asset sale needs NHS England's approval of the buyer's change of ownership application; a share sale leaves the company on the pharmaceutical list, with 30 days to notify NHS England of new directors or a new superintendent. The process takes time and must run in parallel with the legal completion process, not after it. Triggering it early and building it into the overall transaction plan prevents it from becoming the delay that holds up completion.

The buyer has regulatory steps too: the premises entry in the GPhC register depends on the person lawfully running the pharmacy there (Medicines Act 1968 ss74A, 74B), and a buying company needs a superintendent pharmacist (s71). These are regulatory steps that need to be mapped at the start of the final twelve months, not discovered at the point of exchange.

Structure decisions and their tax consequences interact with BADR eligibility: a sale of shares in a personal company has different conditions from a sale of a sole-trader or partnership business. The structure should be agreed, with specialist input, before heads of terms are signed. For a full treatment of the share versus asset decision, see the share vs asset purchase post.

What a specialist does across the timeline

Exit planning over a two to three year horizon is not a one-off engagement. The work that moves the outcome spans phases.

In the early period, the specialist role is diagnostic: checking BADR qualifying conditions, reviewing the accounts coding, and flagging restructuring risks before they are accidentally triggered. In the mid period, it is modelling: running a gain estimate against the lifetime limit, the basic-rate band, and the expected deal structure so there are no surprises at heads of terms. In the final twelve months, it is co-ordination: preparing the data-room accounts, running the margin-story document, timing the disposal date decision, and managing the regulatory and legal workstreams in parallel.

At completion, the CGT computation and filing obligations (within 60 days for any residential element; Self Assessment for the main gain) are live deadlines with penalties for late filing. The post-deal period also includes any earn-out tracking, warranty and indemnity positions, and the closing of the company if the sale was a share deal and the buyer then winds the entity down.

The selling a pharmacy hub sets out how specialist support maps across the sale process. To talk through the timeline for your situation and run an initial sense-check on the BADR and CGT position, get in touch or see the pharmacy sale CGT and BADR service page.

Frequently asked questions

Two to three years is the practical minimum. The BADR two-year qualifying period, the time needed to produce clean reconciled accounts, and the NHS regulatory change-of-ownership process all run on long lead times. Starting earlier gives you more control over each variable.

Business Asset Disposal Relief charges CGT at 18% for 2026/27 on qualifying gains up to the £1m lifetime limit per person. From 6 April 2027 the lifetime limit is due to fall from £1 million to £500,000 (announced at Budget 2026 on 28 October 2026, still to pass in the Finance Bill). The rate was 14% in 2025/26 and 10% before that. Source: gov.uk/business-asset-disposal-relief.

The disposal date (normally the date of exchange of contracts, not completion) determines which BADR rate applies. Special rules apply where contracts are exchanged before 6 April 2027 but complete on or after it: the £500,000 limit can still apply unless the parties to the contract can show it was not entered into to gain a tax advantage from the timing (and, where they are connected, that it was for wholly commercial reasons), so exchanging early is not a safe way to keep the £1m limit. If your exit is within the next 12 to 24 months, the current 18% rate for 2026/27 applies unless the rate changes in a future Budget. The £1m lifetime limit (due to fall to £500,000 for disposals from 6 April 2027, announced at Budget 2026 on 28 October 2026 and not yet law) is per person, so checking how much you have already used matters before agreeing heads of terms.

The core value levers are: NHS contract strength measured by item volume and contract type, a clean and evidenced margin story with Drug Tariff variances annotated, a consistent VAT retail-scheme record, and growing service income such as Pharmacy First coded separately. A buyer pays for earnings quality they can verify.

It can. A fixed deferred amount is taxed in full at the date of disposal, before you receive it (TCGA 1992 s48), though if it's paid in instalments over more than 18 months you can ask to pay the tax in instalments too (s280). A contingent earn-out works differently: the value of your right to the future payments is taxed at the disposal, and each later payment is a disposal of that right, which doesn't get the relief given on the original sale, BADR included (HMRC manual CG14970).

A share sale means the buyer acquires the company's full history and pays 0.5% stamp duty on shares (a charge the Securities Transfer Tax is announced to replace in late 2027). An asset sale means SDLT on any property at non-residential rates up to 5%, and the buyer acquires only the selected assets. The choice affects the buyer's DD risk, the BADR calculation, and the goodwill relief position. It should be agreed before heads of terms, not after.

Related reading

Need help with your pharmacy finances?

Tell us about your situation and we will come back within 24 hours.

Step 1 of 2 · About you

Optional: a bit more detail (helps us prepare)